Overview

The Effects of Alendronate After Cure of Primary Hyperparathyroidism

Status:
Withdrawn
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
We are investigating whether, after surgical cure of primary hyperparathyroidism, alendronate provides even greater beneficial skeletal effects than parathyroidectomy alone. Primary Hyperparathyroidism (PHPT) is a disorder that can be associated with bone loss. After successful surgery for PHPT bone density improves without any treatment. However, it is possible that bone density might improve to an even greater extent if Fosamax is used after the surgical cure. Fosamax is approved by the FDA for the prevention and treatment of osteoporosis, and the goal of this project is to determine whether after successful surgical cure of PHPT, Fosamax is even better for the skeleton than just parathyroid surgery alone.
Phase:
Phase 4
Details
Lead Sponsor:
Columbia University
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Alendronate